SCCPDH Inhibitors
Chemical inhibitors of SCCPDH can regulate the enzyme's activity through diverse biochemical mechanisms. Trichostatin A, for instance, acts as a histone deacetylase inhibitor, leading to increased acetylation of histones and altering gene expression. This change in gene expression can influence the metabolic pathways in which SCCPDH operates, thereby modulating its activity. Similarly, MG-132, a proteasome inhibitor, prevents the degradation of ubiquitinated proteins, which may result in the accumulation of proteins that negatively regulate SCCPDH, thus inhibiting its function. Allopurinol, by inhibiting xanthine oxidase, affects purine metabolism and can alter the levels of metabolites that regulate SCCPDH activity through feedback inhibition. In addition, Methotrexate, which impacts the folate pathway by inhibiting dihydrofolate reductase, can alter the availability of substrates or cofactors necessary for SCCPDH, leading to its inhibition.
Moreover, inhibitors like 5-Fluorouracil, which targets thymidylate synthase, can impact SCCPDH by disrupting the balance of nucleotide pools, an effect that stems from the interconnectedness of metabolic pathways. The activity of SCCPDH can also be influenced by Ritonavir, which inhibits cytochrome P450 3A4, thus affecting drug metabolism pathways that intersect with SCCPDH's metabolic pathways. Compounds such as Epigallocatechin gallate and Omeprazole can alter the enzymatic landscape in which SCCPDH functions, either by influencing cellular signaling enzymes or by affecting systemic physiological processes like gastric pH, respectively. Rapamycin's role as an mTOR inhibitor leads to broad effects on cell growth and protein synthesis, potentially reducing the metabolic flux through SCCPDH's pathways. Zidovudine's inhibition of reverse transcriptase can decrease the demand for the metabolic intermediates that SCCPDH helps produce. Lastly, compounds like Leupeptin and Sodium orthovanadate can modulate SCCPDH activity through the inhibition of proteases and phosphatases, respectively, affecting the turnover and post-translational state of proteins that regulate SCCPDH.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. SCCPDH's activity involves metabolic pathways where histone acetylation can regulate gene expression, leading to altered enzyme activity. By inhibiting histone deacetylase, Trichostatin A would result in increased acetylation, thereby changing the expression of enzymes in the same pathway as SCCPDH, leading to its functional inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. SCCPDH, like many metabolic enzymes, could be regulated by proteasomal degradation. Inhibition of the proteasome by MG-132 could increase the levels of regulatory proteins that suppress SCCPDH activity, thereby inhibiting its function. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $128.00 | ||
Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid. As SCCPDH is involved in purine metabolism, the inhibition of xanthine oxidase by Allopurinol can lead to alterations in metabolite levels that indirectly inhibit SCCPDH activity due to feedback mechanisms within the purine synthesis pathway. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate is a dihydrofolate reductase inhibitor that affects the folate pathway. Since SCCPDH is part of the broader metabolic network, alterations in folate metabolism can indirectly influence the availability of substrates or cofactors necessary for SCCPDH function, leading to its inhibition. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil is an inhibitor of thymidylate synthase, affecting DNA synthesis. SCCPDH, through its metabolic contributions, could be impacted by the perturbations in nucleotide availability, resulting in functional inhibition due to the interconnected nature of metabolic pathways. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $122.00 | 7 | |
Ritonavir is known to inhibit cytochrome P450 3A4. This enzyme is involved in the metabolism of various drugs and can indirectly influence the activity of SCCPDH by altering drug metabolism pathways that interact with the metabolic pathways SCCPDH is involved in. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate (EGCG) is a catechin found in green tea, known to inhibit various enzymes involved in cellular signaling pathways. By inhibiting these enzymes, EGCG can alter the metabolic state of the cell and indirectly lead to the inhibition of SCCPDH by modifying the cellular environment it operates within. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $66.00 | 4 | |
Omeprazole is a proton pump inhibitor that alters gastric pH. Through its systemic effect on gastric acidity and subsequent impact on digestion and absorption, omeprazole can influence the metabolic status of the cell and indirectly inhibit SCCPDH by altering its substrate availability. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor and affects cell growth and proliferation. By inhibiting mTOR, rapamycin can lead to a reduction in protein synthesis and cellular metabolism. This reduced metabolic activity can indirectly inhibit SCCPDH by decreasing the overall metabolic flux through pathways in which SCCPDH is active. | ||||||
3′-Azido-3′-deoxythymidine | 30516-87-1 | sc-203319 | 10 mg | $60.00 | 2 | |
Zidovudine is a reverse transcriptase inhibitor. By inhibiting reverse transcriptase, zidovudine can lead to decreased DNA synthesis, which could indirectly inhibit SCCPDH by reducing the demand for metabolic intermediates that SCCPDH helps to produce. | ||||||